Brainsway Ltd. (BWAY)
About Brainsway Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $556.9M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $556.9M
- Shares outstanding
- 34.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 17, 2019
Brainsway Ltd. (BWAY) Stock Price
- Trading 7% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Brainsway Ltd..
Write a review
News about Brainsway Ltd.
News & sentiment via Polygon.io
Brainsway Ltd.: frequently asked questions
Is Brainsway Ltd. an American company?
Brainsway Ltd. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Brainsway Ltd. publicly traded?
Yes — Brainsway Ltd. is a publicly traded company. Its stock trades under the ticker symbol BWAY on the NASDAQ.
What does Brainsway Ltd. do?
Brainsway Ltd. is an American Medical Devices company in the Health & Beauty sector.
When was Brainsway Ltd. founded?
Brainsway Ltd. was founded in 2003.
